Figure 2.

Ex Vivo MYXV Virotherapy of an Allogeneic BM Transplant against Residual MOPC315.BM Myeloma Burden

(A) The experimental workflow is outlined. (B) Survival of animals was monitored following establishment of residual MOPC315.BM DsRed burden and treating with either no transplant (n = 20), untreated BM transplant from C57BL/6 mice (n = 20), or BM transplant from C57BL/6 mice pre-treated ex vivo with vMyx-135KO-EGFP for 1 hr at MOI of 10 (n = 19). (C and D) Myeloma burden was measured in the spleen (C) or BM (D) of the studied animals using flow cytometry to quantify percentage of total cells that are CD138⁺, DsRed⁺ MOPC315.BM DsRed cells. Significance in survival and tumor burden were determined using the log rank test and the Student t test, respectively. p < 0.05 is deemed significant. N.S., not significant.